Monogram Orthopaedics Amends Merger Agreement with Zimmer Biomet

Monogram Orthopaedics Inc ( (MGRM) ) has issued an announcement.

Monogram Orthopaedics Inc., a Delaware corporation, entered into a merger agreement with Zimmer Biomet Holdings, Inc. and its subsidiary, Honey Badger Merger Sub, Inc. On August 27, 2025, the companies amended the merger agreement following a comment from the SEC, specifically altering the definition of ‘Permitted Transfer’ in the CVR Agreement.

The most recent analyst rating on (MGRM) stock is a Buy with a $10.80 price target. To see the full list of analyst forecasts on Monogram Orthopaedics Inc stock, see the MGRM Stock Forecast page.

Spark’s Take on MGRM Stock

According to Spark, TipRanks’ AI Analyst, MGRM is a Neutral.

Monogram Orthopaedics Inc. shows promise due to significant technological advancements and recent regulatory clearances, which are key drivers for potential growth. However, financial instability, regulatory uncertainties, and ongoing profitability challenges weigh heavily on the overall score. The stock’s upward momentum is a positive indicator, but valuation metrics remain weak due to negative earnings and lack of dividends.

To see Spark’s full report on MGRM stock, click here.

More about Monogram Orthopaedics Inc

Average Trading Volume: 366,044

Technical Sentiment Signal: Buy

See more data about MGRM stock on TipRanks’ Stock Analysis page.